Guggenheim raises Edgewise Therapeutics stock price target on Servier deal
Guggenheim raised its price target for Edgewise Therapeutics (NASDAQ:EWTX) to $51 from $41, maintaining a Buy rating after the planned sale of Edgewise's muscular dystrophy business unit to Servier for up to $2.65 billion. The upgrade was also supported by positive Phase 2 CIRRUS Part D data for EDG-7500, showing strong efficacy in hypertrophic cardiomyopathy, positioning it as a competitor to existing cardiac myosin inhibitors. This follows similar price target adjustments by other firms like RBC Capital and Goldman Sachs, despite a recent stock decline.
Guggenheim raises Edgewise Therapeutics stock price target on Servier deal By Investing.com
Guggenheim has increased its price target for Edgewise Therapeutics (EWTX) to $51 from $41, maintaining a Buy rating, following the planned sale of Edgewise's muscular dystrophy unit to Servier for up to $2.65 billion. The firm also cited strong efficacy data for EDG-7500 in hypertrophic cardiomyopathy, positioning it as a strong competitor. Despite the stock's significant surge, InvestingPro suggests it may be overvalued, though the company's strong cash position is a positive indicator.
If You Invested $1,000 in Edgewise Therapeutics, Inc. (EWTX)
This article analyzes the historical performance of Edgewise Therapeutics, Inc. (EWTX) stock, detailing potential returns for $1,000 investments made one, five, and ten years ago, as well as since its IPO. It further provides an in-depth company overview, highlighting its focus on developing therapeutics for muscular dystrophies and cardiac conditions, its key product candidates in clinical trials, and critical business and regulatory information. The piece emphasizes the company's clinical-stage status, lack of product revenue, and inherent risks associated with biopharmaceutical development.
EWTX - Edgewise Therapeutics Inc Earnings
This article provides a comprehensive financial overview of Edgewise Therapeutics Inc (EWTX), detailing its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It includes data on market capitalization, income, sales, EPS, and various ratio analyses. The company is in the Biotechnology sector, with a recent closing price of $39.56 and significant year-over-year growth.
Edgewise Therapeutics (EWTX) CSO exercises 200K options and sells 200K shares
Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, executed an exercise-and-sell transaction involving 200,000 shares of company stock. He exercised options to acquire 69,648 shares at $0.18 and 130,352 shares at $0.45, then simultaneously sold all 200,000 shares at an average price of approximately $39.40. Following these transactions, Russell directly holds 94,203 shares of common stock and retains over a million stock options with a $0.18 exercise price.
Form 4 Edgewise Therapeutics Inc For: 2 July By Investing.com
This article announces the filing of Form 4 for Edgewise Therapeutics Inc. on July 2. Form 4 filings typically report changes in beneficial ownership of company securities by insiders. The article includes the company's stock symbol EWTX and notes a recent gain of 1.05%.
Edgewise Therapeutics chief scientific officer Alan Russell sells $7.88m By Investing.com
Edgewise Therapeutics' Chief Scientific Officer, Alan Russell, sold 200,000 shares of the company's common stock for approximately $7.88 million on July 1, 2026, after exercising stock options. The sale occurred while the stock was near its 52-week high and deemed overvalued by InvestingPro. Russell now directly holds 24,555 shares after these transactions.
Edgewise Therapeutics chief scientific officer Alan Russell sells $7.88m
Edgewise Therapeutics' Chief Scientific Officer, Alan J Russell, sold 200,000 shares of company stock for over $7.88 million. This sale followed his exercise of stock options to acquire the shares earlier on the same day. Despite positive analyst ratings and trial results for their drug candidate EDG-7500, the company's stock fell 25% after the trial data release, and InvestingPro analysis suggests it is currently overvalued.
EWTX - Edgewise Therapeutics Inc Options
This article provides a detailed financial overview of Edgewise Therapeutics Inc (EWTX), including its market performance, key financial metrics, and company statistics. It highlights the stock's recent close, percentage change, and various financial ratios, along with information on insider and institutional ownership, and price performance over different periods. The data covers market cap, income, sales, EPS, and short interest, offering a comprehensive snapshot of the company's current financial health and market position.
Director Jonathan Fox of Edgewise Therapeutics (EWTX) receives 319-share stock grant
Jonathan C. Fox, a director at Edgewise Therapeutics (EWTX), received a grant of 319 shares of common stock as compensation. These shares were awarded at a price of $0.00 per share, increasing his total direct holdings in the company to 24,833 shares of common stock. This transaction was reported in a Form 4 filing, indicating it was a compensation-related acquisition rather than an open-market purchase.
Form 4 Edgewise Therapeutics Inc For: 1 July By Investing.com
Investing.com reports a Form 4 filing for Edgewise Therapeutics Inc. as of July 1st. The article provides the title of the filing and indicates it was published by Investing.com. It also briefly mentions the financial markets worldwide.
[144] Edgewise Therapeutics, Inc. SEC Filing
This article announces an SEC Form 144 filing by Edgewise Therapeutics, Inc. (EWTX), detailing a proposed sale of 200,000 common shares with an aggregate market value of $8,126,000.00. The shares were acquired through the exercise of stock options on July 1, 2026. The filing indicates a neutral impact and sentiment.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics has granted inducement stock options to two new non-executive employees to purchase a total of 16,500 shares of its common stock. The options, granted on June 30, 2026, have an exercise price of $40.63 per share and will vest over time, contingent on continued employment. This action aligns with Nasdaq Listing Rule 5635(c)(4) and Edgewise's 2024 Inducement Equity Incentive Plan, aiming to attract and retain talent.
EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business
Servier is acquiring Edgewise Therapeutics' muscular dystrophy business for $2.65 billion, including the lead drug candidate Sevasemten. This deal, comprising $1.55 billion upfront and up to $1.1 billion in milestones, caused Edgewise (EWTX) shares to surge over 20% to a record high. Sevasemten is currently in pivotal trials for Becker muscular dystrophy and Phase 2 for Duchenne muscular dystrophy, showing promising safety and efficacy data.
Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release
Edgewise Therapeutics (EWTX) saw a 13.3% increase following the release of positive 12-week Phase 2 Part D CIRRUS-HCM results for EDG-7500. The data indicated clinically meaningful improvements in hypertrophic cardiomyopathy symptoms, heart failure biomarkers, and patient outcomes, alongside preserved systolic function and a well-tolerated safety profile. This positive news strengthens the investment narrative for Edgewise Therapeutics, although it also heightens the reliance on the success of the upcoming Phase 3 trials for EDG-7500.
Edgewise Therapeutics, Inc. Actuals & Estimates (NASDAQ:EWTX)
This article provides an overview of Edgewise Therapeutics, Inc. (EWTX) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates for the income statement, balance sheet, and cash flow, along with information on earnings, revenue, market capitalization, and employee count. The stock has shown significant growth over the past year, and analysts predict a broad price target range with strong buy ratings.
Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release
Edgewise Therapeutics (EWTX) saw a 13.3% increase in its stock price following the release of positive 12-week Phase 2 Part D CIRRUS-HCM results for its drug EDG-7500. The data indicated significant improvements in heart failure symptoms and biomarkers for patients with both obstructive and nonobstructive hypertrophic cardiomyopathy, notably preserving systolic function. While these results bolster the investment narrative for EDG-7500, the company faces challenges including high concentration risk on this single drug, ongoing losses, and a potentially inflated valuation.
EWTX Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Edgewise Therapeutics, Inc. (EWTX) stock, based on analyst ratings. It highlights the stock's recent performance, current market capitalization, and upcoming earnings report. The piece also addresses frequently asked questions about EWTX, including its volatility, historical prices, and how to invest.
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data
RBC Capital has raised its price target for Edgewise Therapeutics (EWTX) to $59 from $48, maintaining an Outperform rating, following positive 12-week results from the '7500 HCM trial. The data showed promising safety and efficacy, potentially simplifying future Phase 3 trial design. Edgewise Therapeutics also recently announced an acquisition agreement with Servier for $1.55 billion upfront, allowing it to focus on its cardiovascular pipeline.
Edgewise Therapeutics (EWTX) Stock Looks Fully Priced After Phase 2 HCM Progress
Edgewise Therapeutics (EWTX) stock has seen significant gains following positive Phase 2 CIRRUS-HCM data for EDG-7500, setting the stage for Phase 3 development. Despite strong recent performance and trading below analyst targets, the company's valuation, marked by an 8x price-to-book ratio compared to a peer average of 4.8x and a broader industry average of 2.2x, suggests the stock is currently overvalued, especially given its lack of revenue and ongoing losses. This premium reflects high market expectations for its clinical pipeline and future growth.
Edgewise Therapeutics (EWTX) Stock Looks Fully Priced After Phase 2 HCM Progress
Edgewise Therapeutics (EWTX) stock has seen significant momentum following positive Phase 2 data for EDG-7500 in hypertrophic cardiomyopathy, leading to plans for Phase 3 development. Despite strong recent gains and trading below analyst targets, the company's high price-to-book ratio of 8x suggests it is overvalued compared to peers and the broader industry, especially given its lack of current revenue and reliance on future clinical success. Investors are advised to consider the risks and weigh the premium against the probability of future approvals and commercialization.
Edgewise Therapeutics (EWTX) director receives grant of 16,377 stock options
Edgewise Therapeutics (EWTX) director and 10% owner Peter A. Thompson received a grant of 16,377 stock options. These options have an exercise price of $35.59 per share and expire on June 5, 2036. The options will vest 100% on the earlier of June 5, 2027, or the business day before the company’s 2027 annual meeting of stockholders.
How Positive CIRRUS-HCM Phase 2 Data and Preserved Systolic Function Will Impact Edgewise Therapeutics (EWTX) Investors
Edgewise Therapeutics (EWTX) has reported positive Phase 2 data for EDG-7500 in hypertrophic cardiomyopathy, showing improved heart function and symptoms while preserving systolic function. This strengthens the company's investment narrative by adding a second key value driver and outlining a path to Phase 3 trials in late 2026. However, investors should be aware of ongoing losses, the absence of revenue, and potential future financing needs.
Edgewise Therapeutics (EWTX) director granted 16,377 stock options at $35.59
Edgewise Therapeutics director Laura Brege was granted 16,377 stock options with an exercise price of $35.59 per share, expiring on June 5, 2036. The options will fully vest on the earlier of June 5, 2027, or the business day before the company's 2027 annual meeting of stockholders. This transaction is a compensation-related award and not an open-market purchase or sale.
Director at Edgewise (NASDAQ: EWTX) awarded 16,377 stock options
Edgewise Therapeutics director Arlene Morris was granted 16,377 stock options with an exercise price of $35.59 per share, expiring on June 5, 2036. These options will vest 100% on the earlier of June 5, 2027, or the business day before the company's 2027 annual meeting of stockholders. This transaction is a compensation-related award and not an open-market purchase or sale.
EWTX Maintained by Goldman Sachs -- Price Target Raised to $32.0
Goldman Sachs has maintained a Neutral rating on Edgewise Therapeutics (EWTX) but significantly raised its price target from $20.00 to $32.00. This adjustment suggests cautious optimism, potentially due to positive developments in the company's product pipeline, despite ongoing uncertainties. EWTX, a biotechnology firm, has a GF Score™ of 30, indicating strong financial strength but weaknesses in profitability and growth, and has seen $4.2 million in insider selling over the last three months.
RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk
RBC has increased its price target for Edgewise Therapeutics (EWTX) to $59 from $48, maintaining an "Outperform" rating with a speculative risk. This adjustment suggests a positive outlook from RBC on the company's future performance. The article also touches upon a recent announcement regarding the sale of Edgewise's muscular dystrophy business to Servier for up to $2.65 billion, which aims to strengthen the company's balance sheet and focus on its cardiovascular pipeline.
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - Slideshow (NASDAQ:EWTX)
Edgewise Therapeutics, Inc. (EWTX) has released a slideshow discussing the top-line data from its EDG-7500 Phase II CIRRUS-HCM trial, which investigates the drug for Hypertrophic Cardiomyopathy. The content specifically refers to a slide deck published by the company in conjunction with this event. This information is intended for investors following the company's progress.
[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity
Edgewise Therapeutics, Inc. director Martin Christopher Nathan reported the grant of 16,377 stock options with an exercise price of $35.59 per share. These options are set to vest on the earlier of June 5, 2027, or the business day before the company's 2027 annual meeting, and will expire on June 5, 2036. The transaction is categorized as neutral in filing impact and sentiment, with Mr. Nathan holding 16,377 derivative securities after the grant.
Edgewise Edges Into Phase III With EDG-7500
Edgewise Therapeutics announced that its drug EDG-7500 is advancing to Phase III trials. This development follows the release of data from Part D of its Phase II trial, which focused on hypotrophic cardiomyopathy. The company's progress marks a significant step in developing new treatments for cardiovascular conditions.
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
Edgewise Therapeutics announced positive top-line results from its 12-week Phase 2 CIRRUS-HCM trial for EDG-7500 in both obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). The trial showed consistent and clinically meaningful improvements in echocardiogram parameters, biomarkers, symptoms, and functional status across both types of HCM, with EDG-7500 being generally well tolerated and showing no relationship with left ventricular ejection fraction (LVEF) reductions below 50%. These results support advancing EDG-7500 into Phase 3 clinical development, targeted for the fourth quarter of 2026.
SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall
U.S. stock futures showed little change on Tuesday, with oil prices declining as investors awaited details on a U.S.-Iran peace agreement. Several companies experienced significant premarket moves, including SpaceX and Rackspace Technology surging, while Edgewise Therapeutics and Huntsman Corporation faced declines.
Edgewise Therapeutics reports positive Phase 2 heart data
Edgewise Therapeutics announced positive 12-week Phase 2 trial results for its hypertrophic cardiomyopathy drug, EDG-7500, which led to a rise in its share price to $38.09. The drug showed improvements in heart performance without significant drops in left ventricular ejection fraction and was well-tolerated. These results support the company's plan to initiate a Phase 3 study in late 2026, following a recent $2.65 billion agreement to sell its muscular dystrophy portfolio.
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
Edgewise Therapeutics announced positive top-line results from its 12-week Phase 2 CIRRUS-HCM trial for EDG-7500 in both obstructive (oHCM) and nonobstructive (nHCM) hypertrophic cardiomyopathy. The data showed consistent and clinically meaningful improvements in echocardiogram parameters, biomarkers, symptoms, and functional status, with EDG-7500 being generally well tolerated and no meaningful reductions in left ventricular ejection fraction (LVEF). The company plans to advance EDG-7500 into Phase 3 clinical development, targeting initiation in the fourth quarter of 2026.
(EWTX) Movement as an Input in Quant Signal Sets
This article from Stock Traders Daily discusses the use of movement as an input in quantitative signal sets for Edgewise Therapeutics Inc. (NASDAQ: EWTX). It highlights weak near-term sentiment with a mid-channel oscillation pattern and presents an exceptional 40.5:1 risk-reward short setup. The article also outlines three AI-generated institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, along with a multi-timeframe signal analysis.
Do New Analyst Upgrades and Option Grants Clarify Edgewise Therapeutics' (EWTX) Long-Term Story?
Edgewise Therapeutics recently announced stock option grants to new non-executive employees and received positive affirmations from Wall Street analysts, boosting its investment narrative. While this external confidence highlights upcoming clinical and regulatory milestones, the company still faces significant risks, including no revenue, substantial net losses, and a potentially high valuation. Investors should weigh these perspectives, considering the company's reliance on future financing and trial execution risks, despite analyst optimism.
Edgewise Therapeutics (EWTX) shareholders approve directors, KPMG and executive pay
Edgewise Therapeutics (EWTX) shareholders at their Annual Meeting on June 4, 2026, elected three Class II directors—Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D.—to serve until the 2029 annual meeting. They also ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers.
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
Edgewise Therapeutics (EWTX) stock remains a "Buy" following the transformative $2.65 billion sale of its muscular dystrophy program to Servier, which includes $1.55 billion in upfront cash. This cash infusion will fully fund the development of EDG-7500 for oHCM/nHCM, with a phase 3 initiation targeted for Q4 2026. Key 12-week Part D data from the phase 2 CIRRUS-HCM study for EDG-7500 is anticipated in Q2 2026, serving as a crucial catalyst for its progression.
Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Edgewise Therapeutics reported inducement grants to four new employees, as permitted by Nasdaq Listing Rule 5635(c)(4). These grants, consisting of stock options to purchase 39,200 shares of common stock, were approved by the company's compensation committee and have a per share exercise price equal to the closing price on the grant date. The options vest over four years, with a 25% vesting after one year and monthly vesting thereafter, subject to continued employment.
Edgewise Therapeutics Reports Inducement Grants As Permitted By Nasdaq Listing Rules
Edgewise Therapeutics (EWTX) has reported inducement grants, as allowed by Nasdaq Listing Rules. This news was originally sourced from Reuters and is a brief update on the company's compliance with stock exchange regulations.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics announced it granted inducement stock options for 74,000 shares of common stock to four new non-executive employees on May 29, 2026. These grants, with an exercise price of $34.16 per share, are part of the company's 2024 Inducement Equity Incentive Plan and vest over four years, subject to continued employment, in accordance with Nasdaq Listing Rules. The company specializes in developing novel therapeutics for muscular dystrophies and serious cardiac conditions.
New Edgewise hires get 74,000 stock options as hiring inducement
Edgewise Therapeutics (Nasdaq: EWTX) has granted inducement stock options for 74,000 shares to four new non-executive employees, as permitted by Nasdaq Listing Rules. The options, with an exercise price of $34.16 per share, will vest over four years, with a 25% initial tranche after one year and monthly thereafter. This move aims to attract and retain talent following strategic developments like the sale of its muscular dystrophy business and a focus shift to its cardiovascular pipeline.
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
Edgewise Therapeutics (EWTX) stock reached an all-time high after announcing a definitive agreement to sell its lead muscular dystrophy asset, sevasemten, and related neuromuscular business to Servier for a potential value of up to $2.65 billion. This strategic move allows Edgewise to become a pure-play cardiovascular biotechnology company, focusing its resources on its cardiovascular pipeline. The divestiture provides substantial financial resources and strategic clarity, positioning EWTX to advance its lead candidate EDG-7500 and other cardiovascular programs.
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
Edgewise Therapeutics (EWTX) stock surged 17.9% to an all-time high after announcing a deal to sell its lead muscular dystrophy asset, sevasemten, and related business to Servier for up to $2.65 billion. This transaction positions Edgewise to become a pure-play cardiovascular biotechnology company, strengthening its financial standing and allowing it to focus on its cardiovascular pipeline. Servier gains immediate entry into the Becker and Duchenne muscular dystrophy markets with a late-stage clinical asset.
Edgewise Therapeutics (EWTX) to sell sevasemten business to Servier for up to $2.65B
Edgewise Therapeutics announced a definitive agreement to sell its sevasemten muscular dystrophy business to Servier for an upfront payment of $1.55 billion and potential milestone payments up to an additional $1.1 billion, totaling $2.65 billion. This transaction will allow Edgewise to strengthen its balance sheet and strategically refocus on its cardiovascular pipeline, including the development of EDG-7500 and EDG-15400. The deal is expected to close in Q3 2026, subject to customary conditions.
Press Release: Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Edgewise Therapeutics has announced the sale of Sevasemten for up to $2.65 billion. This transaction aims to strengthen the company's balance sheet and allow it to focus on its cardiovascular pipeline. The deal highlights a strategic shift for Edgewise Therapeutics.
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
Servier has announced it will acquire the muscular dystrophy business of Edgewise Therapeutics for up to $2.65 billion, including an upfront payment of $1.55 billion. The acquisition includes sevasemten, an investigational treatment for Becker and Duchenne muscular dystrophies, with the aim of strengthening Servier's position in rare neurology and neuromuscular disorders. The transaction is expected to close in the third quarter of 2026, pending regulatory clearance.
Wedbush raises Edgewise Therapeutics stock price target on Servier deal
Wedbush has increased its price target for Edgewise Therapeutics (NASDAQ:EWTX) to $52 from $46, maintaining an Outperform rating, following the company's $1.55 billion upfront cash plus $1.1 billion in milestone payments asset sale agreement with Servier for sevasemten rights. This transaction allows Edgewise to concentrate on its cardiac programs, extends its financial runway, and is seen positively by Wedbush. The firm identifies the CIRRUS readout in Q2 2026 as a key near-term catalyst, expecting comparable efficacy and favorable safety outcomes.
Servier buys into muscular dystrophy with potentially $2.7B deal
Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business in a deal potentially worth $2.7 billion. The acquisition centers on sevasemten, an experimental tablet for Duchenne and Becker muscular dystrophies, with Servier paying $1.55 billion upfront and up to $1.1 billion more in milestones. This move is part of Servier's "deep transformation" strategy to expand into neurology and build a more innovative pipeline, while Edgewise will pivot to focus on its cardiovascular drug pipeline.
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
This article details three significant deals in the pharmaceutical industry: Eli Lilly's licensing agreement with Hanmi for a GLP-2 therapy, Servier's acquisition of Edgewise Therapeutics' muscular dystrophy business, and Avenzo Therapeutics' merger agreement with Rallybio to go public. These transactions highlight continued investment in rare diseases, oncology, and gastrointestinal conditions, with substantial financial agreements and strategic advancements in their respective pipelines.
